Hepatitis C, which affects nearly 50 million people worldwide, is a potentially fatal disease. People who inject drugs account for up to 70% of cases worldwide. In France, since 2004, Inserm, ANRS MIE, Santé publique France and Tours University Hospital have been conducting the Coquelicot survey to estimate the prevalence and incidence of hepatitis C among drug users receiving care in treatment and harm reduction services. The latest results from this survey were published in the October issue of the journal Nature Communications. They show a reduction of at least 50% in the prevalence and incidence of the disease among these populations. According to the authors, this decline likely reflects the combined effect of the scale-up of direct-acting antivirals and harm reduction policies. France is currently at a turning point and could achieve the WHO’s targets for the elimination of hepatitis C by 2030.
Source : Inserm
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.